On Friday, the White House revealed that the federal government has nearly 17 million doses of monkeypox vaccine stockpiled at a manufacturing plant in Denmark.
According to reports, the U.S.-owned doses in Denmark—roughly 1 million of which are already vialed, labeled, packaged, and ready for delivery.
The doses have yet to be shipped in the U.S. because the Food and Drug Administration has not conducted a “timely inspection” of the Bavarian Nordic facility where the shots are being stored.
It was reported that the doses could only be delivered if the FDA conducted a new inspection.
Aside from the monkeypox vaccine doses, it was also further learned that the U.S. has enough vaccine substance at the facility in Denmark to produce some 15.8 million more doses.
Meanwhile, a Biden administration official on Friday did not dispute the stockpiles detailed by Krellenstein and Wilkinson but dismissed the idea that the president could override the FDA.
“The FDA is the gold standard and has an obligation to ensure only products that meet its standards for the American people, including its vaccines,” the official said.
“The FDA is also an independent regulatory agency, and keeping it independent is a priority for the administration on all issues,” the official added.